Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > October 2012 - Volume 32 - Issue 5 > Add-on Treatment of Quetiapine for Fibromyalgia: A Pilot, Ra...
Journal of Clinical Psychopharmacology:
doi: 10.1097/JCP.0b013e318267b8ca
Brief Reports

Add-on Treatment of Quetiapine for Fibromyalgia: A Pilot, Randomized, Double-Blind, Placebo-Controlled 12-Week Trial

Potvin, Stéphane PhD*; Morin, Mélanie MSc; Cloutier, Christian MD; Gendron, Alain PhD‡§∥; Bissonnette, Alain MD; Marchand, Serge PhD

Supplemental Author Material
Collapse Box


Abstract: Recently, second-generation antipsychotic drugs have attracted interest in the treatment of chronic pain, including fibromyalgia (FM). Preliminary uncontrolled studies have shown that quetiapine treatment may be helpful for FM patients. In this trial, we sought to examine—for the first time—the efficacy and tolerability of quetiapine as a treatment for FM and its associated psychiatric symptoms. This was a 12-week double-blind, randomized, placebo-controlled trial of quetiapine XR as an add-on treatment for FM syndrome. Fifty-one female FM patients were randomized, and a flexible dosage of 50 to 300 mg/d was used. The primary outcome was the change from baseline to end point in the Fibromyalgia Impact Questionnaire total score. Secondary outcomes included mood symptoms, sleep disturbances, and tender points. Using a low dose (mean = 132.2 mg) of quetiapine, we observed significant benefits of drug treatment on sleep, uncertain effects on FM and mood symptoms, but no effects on pain, in a small group of polymedicated FM patients. Quetiapine was generally well tolerated.

© 2012 Lippincott Williams & Wilkins, Inc.


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.